City of Hope presented phase 3 clinical trial data at the American Society for Radiation Oncology (ASTRO) Annual Meeting on Sept. 30, 2024 (IMAGE)
Caption
Caption: City of Hope presented phase 3 clinical trial data at the American Society for Radiation Oncology (ASTRO) Annual Meeting on Sept. 30, 2024, showing that people with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time. “The introduction of immunotherapy marked the first significant breakthrough in treating small cell lung cancer treatment in decades. Now, we see that if you give immunotherapy concurrently with chemoradiation, it does not yield the same survival benefit as it does when we add it after standard treatment,” said lead author Kristin Higgins, M.D., a radiation oncologist, clinical professor and chief clinical officer at City of Hope Cancer Center Atlanta.
Credit
Photo credit: City of Hope
Usage Restrictions
n/a
License
Licensed content